Report copyright - ARTICLE IN PRESS ACCEPTED FOR PUBLICATION IN ......prognostic factors for poor survival in PDAC [8,9]. Masitinib is a potent oral tyrosine kinase inhibitor (TKI) that targets a limited
Please pass captcha verification before submit form